ArticleRheumatology and therapy2023

Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study.

Clifton O Bingham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.